FIELD: biotechnology.
SUBSTANCE: invention relates to an isolated peptide having the ability to induce cytostatic T-lymphocytes (CTL) in the presence of antigen-presenting cells (APCs) bearing HLA-A*0201 or HLA-A*2402 antigen. This invention discloses compositions comprising the said peptide that are used to induce an immune response against a malignant tumour expressing TOPK or for treatment of a malignant tumour expressing TOPK and a vector for expression of such a peptide. This invention also discloses a method for APC induction and a method for CTL induction using said the peptide, as well as isolated APC and CTL and methods for induction of an immune response against a malignant tumour expressing TOPK.
EFFECT: invention allows to expand the arsenal of means for treatment and induction of the immune response against malignant tumours expressing TOPK.
12 cl, 8 dwg, 3 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| UBE2T PEPTIDE AND VACCINES CONTAINING THE SAME | 2013 |
|
RU2663350C2 |
| KNTC2 PEPTIDES AND VACCINES CONTAINING THE SAME | 2014 |
|
RU2671395C2 |
| FOXP3 PEPTIDE VACCINE | 2007 |
|
RU2473557C2 |
| HJURP PEPTIDES AND VACCINES CONTAINING THEM | 2011 |
|
RU2570560C2 |
| PEPTIDE VACCINES FOR CANCER EXPRESSING MPHOSPH1 OR DEPDC1 POLYPEPTIDES | 2007 |
|
RU2469044C2 |
| MPHOSPH1 PEPTIDES AND VACCINES CONTAINING THEM | 2012 |
|
RU2612905C2 |
| TEM8 PEPTIDES AND VACCINES CONTAINING THEM | 2008 |
|
RU2498993C2 |
| EPITOPE WDRPUH PEPTIDES AND VACCINES, CONTAINING THEM | 2009 |
|
RU2514386C2 |
| NEIL3 PEPTIDES AND VACCINES INCLUDING SAME | 2010 |
|
RU2600888C2 |
| PEPTIDE CANCER VACCINES EXPRESSING TUMOUR-SPECIFIC ANTIGENS | 2008 |
|
RU2464275C2 |
